Simulations Plus, Inc.
SLP
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounā¦ read more
Healthcare
Health Information Services
29 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$18.25
Price+0.06%
$0.01
1Y
Price
Market Cap
$369.103m
Small
Price/Earnings 3y Avg5y Avg
20.7x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+26.1%
EBITDA Margin-330.6%
Net Profit Margin+38.5%
Free Cash Flow Margin+26.1%
EBITDA Margin-330.6%
Net Profit Margin+38.5%
Free Cash Flow MarginRevenue
$79.179m
+14.8%
1y CAGR+14.3%
3y CAGR+14.7%
5y CAGREarnings
-$64.718m
-734.9%
1y CAGR-251.7%
3y CAGR-181.9%
5y CAGREPS
-$3.22
-742.9%
1y CAGR-253.7%
3y CAGR-183.4%
5y CAGRBook Value
$124.801m
$131.936m
Assets$7.135m
Liabilities$616k
DebtDebt to Assets
0.5%
-
Debt to EBITDAFree Cash Flow
$17.413m
+2.2%
1y CAGR+0.3%
3y CAGR-1.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company